Requirement of oestrogens for the sensitivity of prolactin cells to vasoactive intestinal peptide in rats and man.

Pizzi M, Rubessa S, Simonazzi E, Zanagnolo V, Falsetti L, Memo M, Spano PF

The Journal of endocrinology1 Feb 1992Cited by 6 (Europe PMC)

PMID1541929DOI10.1677/joe.0.1320311PepBankPUB-01541929

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In fertile women, intravenous vasoactive intestinal peptide at 1 microgram/kg increased plasma prolactin levels.
In plain wordsIn fertile women, an injection of VIP raised blood prolactin.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePlasma prolactin after VIP in fertile women
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
Intravenous injection of VIP (1 microgram/kg) to fertile women increased plasma prolactin levels and heart rate and reduced diastolic pressure.
Report a problemFND-0154192901
02HumanNon-randomized trialEfficacy outcome
In fertile women, intravenous vasoactive intestinal peptide at 1 microgram/kg increased heart rate.
In plain wordsIn fertile women, an injection of VIP raised the heart rate.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseHeart rate after VIP in fertile women
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
1 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
Intravenous injection of VIP (1 microgram/kg) to fertile women increased plasma prolactin levels and heart rate and reduced diastolic pressure.
Report a problemFND-0154192902
03HumanNon-randomized trialEfficacy outcome
In fertile women, intravenous vasoactive intestinal peptide at 1 microgram/kg reduced diastolic pressure.
In plain wordsIn fertile women, an injection of VIP lowered diastolic blood pressure.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseDiastolic pressure after VIP in fertile women
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
1 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
Intravenous injection of VIP (1 microgram/kg) to fertile women increased plasma prolactin levels and heart rate and reduced diastolic pressure.
Report a problemFND-0154192903
04HumanNon-randomized trialEfficacy outcome
In menopausal women, intravenous vasoactive intestinal peptide did not modify plasma prolactin levels.
In plain wordsIn menopausal women, an injection of VIP did not change blood prolactin.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changePlasma prolactin after VIP in menopausal women
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
1 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
The same treatment to menopausal women caused similar cardiovascular effects but did not modify plasma prolactin levels.
Report a problemFND-0154192904
05HumanNon-randomized trialEfficacy outcome
In menopausal women, intravenous vasoactive intestinal peptide caused cardiovascular effects similar to those in fertile women.
In plain wordsIn menopausal women, an injection of VIP had heart and blood pressure effects similar to those in fertile women.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
MixedCardiovascular effects of VIP in menopausal women
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
1 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
The same treatment to menopausal women caused similar cardiovascular effects but did not modify plasma prolactin levels.
Report a problemFND-0154192905

Studies that did not test the peptide alone3

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism
In pituitary cells from rats 3 or 4 weeks after ovariectomy, the prolactin response to vasoactive intestinal peptide was completely suppressed.
In plain wordsIn cells from rats, removal of the ovaries stopped the pituitary cells from responding to VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseSensitivity of prolactin release to VIP after ovariectomy
Study
ratn: not reported in source
Pituitary cells from ovariectomized rats
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
The sensitivity of rat mammotrophs to VIP, but not to TRH, was completely suppressed 3 or 4 weeks after ovariectomy.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0154192906
07LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism
In pituitary cells from ovariectomized rats, an oestradiol-17 beta implant preserved the cell response to vasoactive intestinal peptide.
In plain wordsIn cells from rats, an oestradiol implant kept pituitary cells responsive to VIP after ovary removal.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePreservation of VIP responsiveness by oestradiol implant
Study
ratn: not reported in source
Pituitary cells from ovariectomized rats with oestradiol-17 beta capsule
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Furthermore, implantation of rats with a silastic capsule containing oestradiol-17 beta during ovariectomy, preserved the cell responsiveness to VIP.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0154192907
08LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Mechanism
In pituitary cells from ovariectomized rats, culture with oestradiol-17 beta for 3 days restored the prolactin-releasing property of vasoactive intestinal peptide.
In plain wordsIn cells from rats, oestradiol in the dish brought back the prolactin response to VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseRestoration of VIP prolactin-releasing response by oestradiol in culture
Study
ratn: not reported in source
Pituitary cells from ovariectomized rats cultured with oestradiol-17 beta
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
The prolactin-releasing property of VIP was also restored when pituitary cells from ovariectomized rats were cultured for 3 days in the presence of 10 nmol oestradiol-17 beta/l before being used for prolactin release experiments.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0154192908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.